Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...
Hims & Hers shares surged in May after the company said it would begin selling compounded versions of GLP-1 injections. What Happened: The FDA said in a statement late Wednesday that Eli Lilly's ...